Median iCRO helps life sciences companies transform data into life-changing therapies. We understand what’s at stake for your business and offer unprecedented clinical trial imaging insights and expertise. Partnering with Pharma, Biotech, and CROs globally, we help improve business and patient outcomes.
We transform medical images into meaningful, actionable insights to help better diagnose, treat, and monitor patients. We deploy proprietary artificial intelligence, computer vision, and signal processing technologies to develop imaging tests and services, addressing life-threatening unmet medical needs.
With iBiopsy® we are disrupting the management of serious diseases such as lung cancer, liver cancer, and NASH. We are deploying AI/ML Software as Medical Devices (SaMDs) to help health professionals diagnose patients earlier, treat them more effectively, and bring new hope. iBiopsy® is currently under development.
Disclosure of total number of voting rights and number of shares in the capital at September 30th, 2016, pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.